B7-H6 antibody-drug conjugate

B7-H6 antibody-drug conjugate is an experimental therapeutic modality designed to treat B7-H6-expressing malignancies, such as diffuse large B-cell lymphoma (DLBCL). B7-H6 (NCR3LG1) is a tumor-selective surface protein and a ligand for the activating receptor NKp30 on natural killer (NK) cells; it is highly expressed in DLBCL but undetectable in healthy tissues. These ADCs consist of a B7-H6-specific monoclonal antibody conjugated to cytotoxic payloads, such as the microtubule inhibitor monomethyl auristatin E (MMAE) or the topoisomerase I inhibitor DXd. Upon binding to B7-H6 on the tumor cell surface, the ADC is internalized, releasing the payload to induce cell death. Beyond direct cytotoxicity, the ADC may counteract tumor immune evasion by blocking the B7-H6/NKp30 interaction and leveraging Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP).